Quarterly UpdatesJul 2, 2026, 10:36 AM
Unicycive Therapeutics Reports $61.4M Cash Balance
AI Summary
Unicycive Therapeutics, Inc. reported an ending cash balance of approximately $61.4 million as of June 30, 2026. These figures represent preliminary results for the second quarter and have been prepared by management, without audit or review by independent accountants.
Key Highlights
- Ending cash balance of approximately $61.4 million as of June 30, 2026.
- Preliminary results for the second quarter ended June 30, 2026.
Price Impact
More from UNCY